关节内万古霉素预防初次全膝关节置换术后假体周围关节感染:前瞻性双盲随机对照试验
该前瞻性双盲随机对照试验纳入1022例初次全膝关节置换术患者,比较关节内万古霉素粉末(507例,关闭关节囊前给予2克)与对照(515例,不用局部万古霉素)的疗效。结果显示两组假体周围关节感染率无显著差异(0.2% vs 0.58%,P=.264),但万古霉素组轻微伤口并发症显著增多(13.2% vs 7.56%,P<.05)。作者认为关节内万古霉素可能不能有效降低初次全膝关节置换术后假体周围关节感染率。
要点
- 关节内万古霉素组假体周围关节感染率为0.2%,对照组为0.58%,差异无统计学意义(P=.264)。
- 万古霉素组轻微伤口并发症发生率为13.2%,显著高于对照组的7.56%(P<.05)。
- 万古霉素使用(比值比=1.64)和吸烟(比值比=1.85)与轻微伤口并发症风险增加相关。
核心结论
- 关节内万古霉素粉末似乎不能降低初次全膝关节置换术后的假体周围关节感染/手术部位感染率,包括高危人群。
- 尽管从肾脏安全性角度看是安全的,但关节内万古霉素与术后无菌性伤口并发症增加相关。
- 关节内万古霉素可能不能有效降低初次全膝关节置换术后假体周围关节感染率。
研究设计与样本
- 前瞻性双盲随机对照试验,共1022例患者随机分为研究组(507例,关闭关节囊前给予2克关节内万古霉素粉末)和对照组(515例,不用局部万古霉素),最少随访12个月。
- 主要结局为假体周围关节感染或手术部位感染的发生率;次要结局包括缝线脓肿、持续伤口渗液、延迟拆线等相关轻微并发症,以及再手术率和肾毒性发生率。
主要发现
- 1022例患者总体感染率为0.66%。
- 研究组假体周围关节感染率为0.2%(1例),对照组为0.58%(3例),P=.264,无显著差异。
- 研究组再手术率为0.78%(4例),对照组为0.97%(5例);研究组手术部位感染率为0.2%(1例),对照组为0.38%(2例),两组相当。
- 万古霉素组轻微伤口并发症为13.2%(67例),显著高于对照组的7.56%(39例),P<.05。
- 亚组分析显示研究组糖尿病患者轻微伤口并发症发生率更高(24例[14.1%] vs 10例[6.2%],P<.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic joint infection (PJI) after total knee arthroplasty (TKA) is a devastating complication. Intrawound vancomycin powder has been shown to reduce infection rates in spine surgery, but its role in arthroplasty remains controversial. This prospective randomized control trial aimed to evaluate the efficacy of intrawound vancomycin in preventing PJI after primary TKA. METHODS: A total of 1,022 patients were randomized to the study group (n = 507, who received 2 grams intrawound vancomycin powder before arthrotomy closure) or to the control group (n = 515, no local vancomycin) with a minimum follow-up of 12-months. The primary outcome was the incidence of PJI or surgical site infection (SSI). Secondary outcomes included associated minor complications such as stitch abscess, persistent wound drainage, and delayed stitch removal. Other parameters evaluated include reoperation rates and incidences of nephrotoxicity. RESULTS: The overall infection rate in 1,022 patients was 0.66%. There was no significant difference in PJI rate in the study group (N = 1; 0.2%) versus the control group (N = 3; 0.58%), P = .264. Reoperation rates in the study group (N = 4; 0.78%) and control (N = 5; 0.97%), and SSI rates in the study (N = 1; 0.2%) and control groups (N = 2; 0.38%) were comparable. The Vancomycin cohort, however, demonstrated a significantly higher number of minor wound complications (n = 67; 13.2%) compared to the control group (n = 39; 7.56%, P < .05). Subgroup analysis showed diabetics in the study group to also have a higher incidence of minor wound complications (24 [14.1%] versus 10 [6.2%]; P < 05]. Multivariate analyses found that vancomycin use (odds ratio = 1.64) and smoking (odds ratio = 1.85) were associated with an increased risk of developing minor wound complications. No cases of nephrotoxicity were reported. CONCLUSIONS: Intrawound vancomycin powder does not appear to reduce PJI/SSI rate in primary total knee arthroplasties, including high-risk groups. Although safe from a renal perspective, intrawound vancomycin was associated with an increase in postoperative aseptic wound complications. Intrawound vancomycin may not be effective in reducing the rate of PJI in primary TKA.
引用
- Mulpur P, Jayakumar T, Yakkanti RR, et al. Efficacy of Intrawound Vancomycin in Prevention of Periprosthetic Joint Infection After Primary Total Knee Arthroplasty: A Prospective Double-Blinded Randomized Control Trial. J Arthroplasty. 2024. PMID: 38749600. doi:10.1016/j.arth.2024.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。